Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-03-07
2009-12-29
Crane, Lawrence E (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S043000, C514S061000, C514S299000, C514S315000, C514S317000, C514S326000, C514S327000, C514S328000
Reexamination Certificate
active
07638488
ABSTRACT:
The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent.
REFERENCES:
patent: 7256005 (2007-08-01), Zitzmann et al.
patent: 2004/0110795 (2004-06-01), Zitzmann et al.
patent: 2005/0119310 (2005-06-01), Mueller et al.
patent: 2005/0256168 (2005-11-01), Block et al.
Fischer et al., “Treatment for Hepatitis C Virus and Cannabis Use in Illicit Drug User Patients: Implications and Questions,” European Journal of Gastroenterology & Heptatology, 18(10), 1039-1042 (Oct. 2006).
Sylvestre et al., “Cannabis Use Improves Retention and Virological Outcomes in Patients Treated for Hepatitis C,”European Journal of Gastroenterology & Heptatology, 18(10), 1057-1063 (Oct. 2006); only abstract supplied.
O'Neil et al. (eds.), The Merck Index, 13th Edition, Merck & Co., Inc., Whitehouse Station, NJ, 2001, only pp. 5, 321 and 1103-1104 supplied: see in particular entries 18, 1906 & 6210.
(U) Karpas et al., “Aminosugar Derivatives as Potential Anti-Human Immunodeficiency Virus Agents,” Proc. National Academy of Sciences, 85 , 9229-9233 (Dec. 1988).
Chitturi et al., “Hepatotoxicity of Commonly Used Drugs: Nonsteroidal Anti-inflammatory Drugs, Anti-hypertensives, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs,” Semin. Liver Disease, 22(2), 169-183 (2002); only abstract supplied.
Andersson et al., “Inhibition of Glycogen Breakdown by Imino Sugars in vitro and in vivo,” Biochemical Pharmacology, 67(4), 697-705 (Feb. 15, 2004).
Block, T., “Virological Basis of the Broad Antiviral Activity of the Iminosugar Families Called “Glucovirs” and “Alkovirs,” Abstracts of Papers, 230th ACS National Meeting, American Chemical Society, Washington, DC, Aug. 28-Sep. 1, 2005, Abstract No. CARB-041.
Buckvold et al., “Bovine Viral Diarrhea as a Surrogate Model of Heptatiis C Virus for the Evaluation of Antiviral Agents,” Antiviral Research, 60(1), 1-15 (Sep. 2003); PubMed I.D.: 14516916; only PubMed abstract supplied by applicant.
Blatt Lawrence M.
Seiwert Scott
Tan Hua
Cooley Godward Kronish LLP
Crane Lawrence E
Intermune, Inc.
LandOfFree
Use of alpha-glucosidase inhibitors to treat alphavirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of alpha-glucosidase inhibitors to treat alphavirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of alpha-glucosidase inhibitors to treat alphavirus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4132911